Comparative immunogenicity of HIV-1 clade c envelope proteins for prime/boost studies

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Smith, Douglas H ^a   Winters Digiacinto, Peggy ^a   Mitiku, Misrach ^a   O'Rourke, Sara ^b   Sinangil, Faruk ^a,c   Wrin, Terri ^d   Montefiori, David C ^e   Berman, Phillip W ^a,b  

^a VaxGen Inc   (United States)

^b University of California Santa Cruz   (United States)

^c Global Solutions for Infectious Diseases   (United States)

^d MONOGRAM BIOSCIENCES   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PEPTIDE; PROTEIN V3; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; ANTISERUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELL STRAIN HEK293; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; VACCINE PRODUCTION; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; ANTIBODY PRODUCTION; CELL LINE; CLASSIFICATION; COMPARATIVE STUDY; GUINEA PIG; IMMUNIZATION; IMMUNOLOGY; SERODIAGNOSIS;

CAVIA; CERCOPITHECINE HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD4; CELL LINE; GUINEA PIGS; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNE SERA; IMMUNIZATION, SECONDARY; NEUTRALIZATION TESTS;

EID: 77957840131     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012076     Document Type: Article

References (30)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-20.
2. Tartaglia J, Excler JL, El Habib R, Limbach K, Meignier B, et al. (1998) Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses 14 Suppl 3: S291-8.
3. Berman PW (1998) Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses 14 Suppl 3: S277-89.
4. Berman PW, Huang W, Riddle L, Gray AM, Wrin T, et al. (1999) Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology 265: 1-9.
5. Pitisuttithum P, Berman PW, Phonrat B, Suntharasamai P, Raktham S, et al. (2004) Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 37: 1160-5.
6. Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, et al. (2007) Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 44: 203-12.
7. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-71.
8. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, et al. (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-65.
9. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-93.
10. Nkolola JP, Peng H, Settembre EC, Freeman M, Grandpre LE, et al. (2010-00006) Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol 84: 3270-9.
11. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, et al. (2002) Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76: 8875-89.
12. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, et al. (2006) Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80: 11776-90.
13. Pantophlet R, Burton DR (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739-69.
14. JGilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, et al. (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191: 666-77.
15. Powell MF, Eastman D, Lim A, Lucas C, Peterson ML, et al. (1995) Effect of adjuvants in immunogenicity of MN recombinant glycoprotein 120 in guinea pigs. AIDS Res Hum Retroviruses 11: 203-9.
16. Berman PW, Eastman DJ, Wilkes DM, Nakamura GR, Gregory TJ, et al. (1994) Comparison of the immune response to recombinant gp120 in humans and chimpanzees. Aids 8: 591-601.
17. Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR (2008) Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virology 381: 251-60.
18. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-9.
19. Schweighardt B, Liu Y, Huang W, Chappey C, Lie YS, et al. (2007) Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr 46: 1-11.
20. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, et al. (2007) Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81: 6548-62.
21. Johnston MI, Fauci AS (2007) An HIV vaccine-evolving concepts. N Engl J Med 356: 2073-81.
22. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143-55.
23. Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, et al. (2007) A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366: 245-62.
24. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, et al. (2008) Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82: 11651-68.
25. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, et al. (2007) Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13: 1032-4.
26. Lasky LA, Groopman JE, Fennie CW, Benz PM, Capon DJ, et al. (1986) Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 233: 209-12.
27. Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, et al. (2005) HIV- 1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 192: 974-83.
28. Montefiori D (2004) Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. Current Protocols in Immunology. 12.11.1-12.11.15.
29. Saitou N, Nei M (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4: 406-25.
30. Katoh K, Kuma K, Toh H, Miyata T (2005) MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acids Res 33: 511-8.